

# **FIERCE INNOVATION AWARDS** Life Sciences Edition 2023

**INNOVATION REPORT** 



## Introduction

As the immediacy of the COVID-19 pandemic recedes it is clear many of the changes in the Life Sciences industry that were adopted to mitigate disruption are not only here to stay they are the building blocks for the future.

What was perceived just a few years ago as an industry slow to adopt digital technologies, novel therapies and innovative therapy delivery systems are now charging to the forefront of a health-care revolution. Artificial intelligence, machine learning and data collection has changed not only how clinical trials are conducted, but how they are designed before the first patient participant is even signed. These advances are also driving diversity in trials by identifying and recruiting patients from under-represented minority communities.

The advances are also behind serving patient needs that includes real-time monitoring of a patient's condition, alerts to physicians and clinicians of a change in their conditions and tracking their adherence to medications. The technology can also incorporate real-world data and an individual's health history to predict when an adverse medical event is likely to occur.

All of these advances have one goal that remains a constant for Life Sciences—to be patient centric. Whether it's in an organization's mission statement or demonstrated by their products, if you are in the industry your work is directed at getting the right help to the right patient at the right time, and in the most cost efficient manner possible.

This year's Life Sciences Innovation Report reflects those trends. Each year we uncover cutting edge organizations that have or are in the process of launching new technologies and services that are reinventing what it means to be focused on helping people. Each year it gets harder for our judges because there are so many more companies doing great work and making huge strides toward that goal.

Applicants were judged in the following categories:

**Biotech Innovation** - Championing innovation in the face of great competition. This category showcases products and service that are forward thinking and have the greatest opportunity to have an impact on the industry.

**Technology Innovation** - Utilizing technology to shape the industry. This category highlights products and services that are using innovative technology solutions to better serve the industry and promote innovation.

**Data Analytics/Business Intelligence** - Excellence in data analytics. This category recognizes greatness in business intelligence using data science, data management, and data analytics to better serve the industry.

**Digital Health Solution** - Forward thinking digital innovation. This category showcases the best use of digital technology and mobile apps to better serve the industry.

**Drug Delivery Technology** - Drug delivery technologies are shaping the industry. This category recognizes excellence and innovation in the latest drug delivery technologies.

**Medical Device Technology** – Innovative medical devices are a main focus of innovation given advances in materials and production. This category focuses on those advancements and what is in the device pipeline for the future.

Our expert panel of judges reviewed hundreds of applications to find the best of the best and now I am pleased to introduce you to our 2023 winners.



**Rebecca Willumson** Senior Vice President & Publisher Fierce Life Sciences

## **MEET THE JUDGES**



### Wilfredo De Jesus Monge

Founder **clinicaLea** 



Rebecca Willumson Senior Vice President & Publisher Fierce Life Sciences



Chris Jones Chair BrlgID Bio



Daniel Oliver Co-founder and CEO Rejuvenate Bio



Anna Turman Division CIO CommonSpirit Health



Colin Hayward Group Chief Medical Officer TelixPharma





BIOTECH INNOVATION

ELEVIDYS (delandistrogene moxeparvovec-rokl) Sarepta Therapeutics

DATA ANALYTICS/BUSINESS INTELLIGENCE

### **BostonGene**

### BostonGene - Al-based Clinical Trials Matching

BostonGene



#### DIGITAL HEALTH SOLUTIONS

canturio<sup>™</sup>te <sup>Canary Medical</sup> Rant

theranica

TeleScan®

#### DRUG DELIVERY TECHNOLOGY

RaniPill HC Rani Therapeutics

#### MEDICAL DEVICE INNOVATION

Nerivio Migraine Neuroband

#### **TECHNOLOGY INNOVATION**

TeleScan® BB Imaging





#### **BIOTECH INNOVATION**

CEO: DOUGLAS S. INGRAM BASED: CAMBRIDGE, MASSACHUSETTS FOUNDED: 1980 ELEVIDYS (DELANDISTROGENE MOXEPARVOVEC-ROKL)

#### SAREPTA THERAPEUTICS

#### The Science of SRP-9001 (delandistrogene moxeparvovec-rokl)

Duchenne muscular dystrophy is a rare and progressive genetic neuromuscular disease. Predominantly affecting males, Duchenne is linked to the X chromosome and caused by changes or mutations in the *dystrophin* gene. The mutations result in an absence of functional dystrophin protein, which normally acts as a shock absorber when muscles move. The absence of dystrophin leads to progressive muscle weakness and life-threatening complications, including cardiomyopathr, respiratory failure and, utimately, persature death.<sup>13</sup>



Genetic diseases like Duchenne are ideal candidates for gene therapy, which addresses the cause of the disease by providing a functional version of the mutated gene. The goal of SRP-9001 gene therapy is to delay or halt the progression of Duchenne by delivering a modified, functional version of *dystrophin* to muscle cells. The *dystrophin* gene is the largest known human gene. Because of it size, cleinstist had be engineer a shortened version of the gene that could fit inside current gene therapy delivery technologies and still retain the key functional information.<sup>34</sup>



#### WHAT'S THE SCOOP:

After a long journey, Sarepta's Duchenne muscular dystrophy (DMD) gene therapy treatment Elevidys won an accelerated FDA approval in June. The one-time treatment targets the root cause of DMD in patients aged 4- through 5-years-old that despite its \$3.2 million price tag is not only a game changer but a lifesaver. "We're extremely excited about Elevidys," Louise Rodino-Klapac PhD, Sarepta's head of R&D and chief scientific officer, said. "It's really been in development—and I've been with it the entire time—these past 18 years." Three clinical studies found there was meaningful and statistically significant functional improvement in patients treated with Elevidys. Additional clinical evidence showed the treatment also indicated disease stabilization, showing that patients were doing better than the previous natural course the disease would take.

#### WHAT MAKES IT FIERCE:

"The great thing about working at Sarepta is how focused we are," Rodino-Klapac said. "It's a relentless disease and we're working everyday for patients. We don't back down." She added, that knowing that patients are there drives the team to push very hard to get transformative therapies to as many patients as possible.


#### WHAT TO LOOK FOR:

In the near-term, the company is working on broadening the label for Elevidys to treat as many patients as possible. At the same time, Sarepta is working on a number of gene therapies targeting limb girdle muscular dystrophies (LGMD) and other diseases. "We're definitely working hard to stay at the forefront of genetic medicine," she said.

# **BostonGene**

#### DATA ANALYTICS/BUSINESS INTELLIGENCE

CEO: ANDREW FEINBERG BASED: BOSTON FOUNDED: 2015 BOSTONGENE - AI-BASED CLINICAL TRIALS MATCHING



#### WHAT'S THE SCOOP:

BostonGene focuses on cancer patients by leveraging cutting edge sequencing analysis that involves testing a patient's normal DNA in their blood as well their tumor DNA and RNA tissue. Its Al-driven Tumor Portrait platform gives a comprehensive snapshot of what is driving a tumor and pairs the information-in realtime-with information from a patient's health records as well as available drugs or clinical trials specific to their cancer in which they could take part. The platform allows physicians to make more informed treatment options that are specific to the subject's cancer. "It's the most comprehensive snapshot on what is driving the tumor," Nathan Fowler, BostonGene's chief medical officer, said. "There has been a phenomenal change in the field in the last 10 years with the cost of sequencing dropping exponentially, and there are more tools to measure the data that weren't available a decade ago." In a sarcoma trials matching study with MD Anderson Cancer Center, the platform analyzed data from 39 subjects and found more than 97 percent of the reports were eligible for at least one trial at the cancer center, and 30 different biomarker-driven clinical trials also matched. Although nobody wants to be matched with cancer being matched with the appropriate treatment is critical, Fowler said, adding that with the expected explosion of targeted drugs the need to connect patients to therapies will become even more paramount.

#### WHAT MAKES IT FIERCE:

The company's ability to bridge the gaps between the accumulation of the data and the ability to interrogate it. "What we've done is build a really innovative team with a very large group of biologists, immunologists and oncologists and pair them with software engineers," Fowler said. "Very few companies have the two kinds of groups overlapping, which has resulted in more than 150 patented software solutions."

#### WHAT TO LOOK FOR:

The company will be actively pursuing expansion in the U.S. and overseas, Fowler said. Additionally, it will be expanding its pipeline of AI solutions to include drug target applications and adverse event validation.





#### **DIGITAL HEALTH SOLUTIONS**

CEO: BILL HUNTER BASED: VANCOUVER, BRITISH COLUMBIA FOUNDED: 2012 CANTURIO™TE



### FIERCE

#### WHAT'S THE SCOOP:

What's smarter? Having a knee replacement or having a knee replacement that has sensors and a data platform that monitors postoperative progress that can tell if a patient is falling behind recovery expectations or is progressing according to plan? It's an easy answer for Canary Medical CEO Bill Hunter, M.D. "Historically, we've done all these surgical procedures in hospitals then we walk patients to the front door and wish them good luck," he said. "It seemed absurd to me that there might only be a follow up visit a few days or weeks later and then maybe another in a month or so." Enter Persona IQ<sup>®</sup>, a total knee replacement construct that combines Canary Medical's canturio smart stem technology with Zimmer Biomet's Persona line of patientspecific implants. Persona IQ received FDA de novo approval in 2021. Canary Medical's offering features the canturio tibial extension with a sensor, battery and antennae that autonomously monitors postoperative progress and a data analysis platform that automatically alerts health-care providers if a patient needs additional care or is recovering normally. "In the past, you would go to a clinic, and they would test your range of motion to see how you are doing," Hunter said. "Now that's done automatically every day." The data collected is likely to open more doors for the company to move from a purely diagnostic view, to serving as a predictive tool. "You don't walk the same way when you have the flu versus being late for a meeting," he said. "Right now, we're working our way through using AI to track billions of motions and look at those patterns from a predictive perspective."

#### WHAT MAKES IT FIERCE:

The company is bringing an entirely different way of doing things to orthopedics than what has been done in the past, that Hunter said is a much bigger change in healthcare than you might think. "It absolutely changes the way you manage the patient," he said. "People used to go home after knee surgery and not know what is going on. Now they know if they are on pace for recovery or doing too much or too little during recuperation. They go from a passenger, to being actively involved in their recovery process."

#### WHAT TO LOOK FOR:

It isn't much of a technological leap to move from smart knees into smart hip and shoulder replacements. Additionally, Hunter said its existing platform could also eventually be used for spinal surgery. With respect to Al, "I feel that as this data asset grows, we'll go from identification to prediction," Hunter said. "And prediction in medicine is worth its weight in gold."



#### DRUG DELIVERY TECHNOLOGY

CEO: TALAT IMRAN BASED: SAN JOSE, CALIFORNIA FOUNDED: 2012 RANIPILL HC

INTRODUCTION AND STUDY OBJECTIVE		STUDY DESIGN				NCIDENCE C	IF ADV	DEVICE PERFORMANCE		
ni Therapeutics is developing RT-102, a novel, e estible delivery platform robotic pill (RP) conta paratide, as an oral anabolic therapy	ning Saudy was con	Study was conducted at a single site in Australia     End Points: Safety: Tolerability and Pharmacokinetica (PK)				Adverse Events (N=15) (N=14) (N=10)				
ecorosis. As such, this represents a novel route of	drug	Healthy women volunteers were dosed in three groups:     Forteof* SC: 20µg (N=10)     RT-102 Group 1: 20µg (N=15)				AL	0 2 (14%) 5 (50%) 102 was 90% 0 0 2 (20%) • Evaluated by	a) 5 (50%)	<ul> <li>Overall rate of successful drug delivery with R1 102 was 90%</li> </ul>	
very which could potentially affect the kinetics of ake, distribution, and elimination as well as efficacy o b. This phase 1 study evaluated the safety , tolers	the Forteo <sup>®</sup> SC RT-102 Ge					Light headedness		<ul> <li>Evaluated by absence or presence of dru levels in blood samples</li> </ul>		
pharmacokinetic (PK) profiles of teriperatide deli- te RP	ered • RT-102 Ge	<ul> <li>RT-102 Group 2: 80µg (N=15)</li> </ul>			Drug- Related AEs	Nausea	0	1 (7%)	3 (30%)	<ul> <li>RT-102 remnants were excreted withor sequelize</li> </ul>
		phic imaging was done to track the transit of RT- the GI tract and determine T=0 for PK sampling			Vomiting	0	1 (7%)	0		
HOW THE RP WORKS					RP-Related AEs	NA	0	0	NA	and the second sec
	S.	STUDY DEMOGRAPHICS				PHARMACOKINETIC PROFILES AND PARAMETERS				SUMMARY & CONCLUSIONS
		RT-102 20ug	RT-102 80up	Forteo <sup>®</sup> SC 20up				. RT-102-20-PM-	12)	<ul> <li>RT-102 was well-tolerated by all participants</li> </ul>
17 menutes intend in the stormach day is an	N	15	14	10			ι.	<ul> <li>RT-102-80 (N-</li> <li>Parley IDC-20 (</li> </ul>		<ul> <li>No serious adverse events were observed</li> </ul>
2. Enteric Coating Disintegrates in Small Intesting	Age, years	Age, years 31.2 (19 - 61) 31.2 (		2 (20 - 63) 32.6 (10 - 63)	Į	-1	N.			<ul> <li>No adverse events related to the RP were observed</li> </ul>
Trucky diving the	Race White-non-hispanic		78.6% (11/14)	50% (5/10)	ž				<ul> <li>PK data show robust and reproducible PK profiles of PTH delivered via the RP</li> </ul>	
	Hapanic	6.7% (1/15)	78.0% (11/14) 0% (0/14)	10% (1/10)		-	the second se		4	<ul> <li>Bioavailability of PTH delivered orally via th</li> </ul>
Prinding Bail deadon	Asian	6.7% (1/15)	7.1% (1/14)	20% (2/10)		1	20 100	240 240	1	RP was 3-4-fold higher than SC injection
adential matter b presente COj.	Asian-Pacific Islander	0% (0/15)	14.2% (2/14)	20% (2/10)		Forteo SC	Time (r	RT-102 2040	RT-102 80up	<ul> <li>Success rate of drug delivery by RT-102 was env.</li> </ul>
3. Drug is Delivered	Padific lelander	6.7% (1/15)	0% (0/14)	0% (0/10)						Device remnants passed out in all subjects
An british al	Body Mass Index				C <sub>max</sub> (pg/mL)	128 ± 2	10	98 ± 10	971 ± 223	<ul> <li>Device remnants passed out in all subjects without any segualae</li> </ul>
and a state of the	(kg/m²)	23.5 ± 3.9	25 + 3.6	23.6 ± 3.6	T <sub>mat</sub> (minutes)	13		68	60	These data provide evidence of potential of RT
The method bag	Height (an)	104.3 a 7.1	164.4 ± 6.27	162.5 ± 7.7	AUC (pg'himL)	126 ± 6	4	342 ± 38	2600 ± 649	102 to replace current injection therapy for the
	Weight (kg)	611+109	67.4 * 10.2	67 4 + 11 6	Relative BA (%)			~300%	~401%	treatment of osteoporosis.

#### WHAT'S THE SCOOP:

Driven by their mission to alleviate the burden of painful injections, Rani Therapeutics developed a robotic pill, the RaniPill, that delivers biologics orally. The RaniPill's proprietary technology allows the pill to navigate through a patient's stomach and into the small intestine. Once in the small intestine, a small balloon inflates that contains a syringe that injects the medication right into the intestinal wall. It is well-established that the small intestine has no sharp pain receptors, so the patient feels no pain associated with the injection. The RaniPill innovation has the potential to expand the delivery of oral biologics to close to 100 drug candidates and can increase patient adherence to their prescribed medication. "What we set out to do is essentially develop what is a swallowable auto-injector," Talat Imran, Rani's chief executive officer, said. The RaniPill can deliver peptides, antibodies, large proteins, and nucleotides orally. An early version of the RaniPill was limited to delivering only about 3 milligrams of a drug, so the company developed its high-capacity pill, the RaniPill HC. The difference, Imran said, is the HC class, which is undergoing non-human clinical trials, has a liquid delivery system contained in the dissolvable needle that can hold 20 to 30 milligrams. "We have advanced our technology and can now fit about 85 percent of all approved biologics into a RaniPill," he said. "Patients hate injecting

themselves, so instead of taking a large dose that way, they can take a daily pill, the RaniPill." Rani Therapeutics has conducted 15 preclinical studies that demonstrate comparable bioavailability with the RaniPill to the subcutaneous injection and has conducted two clinical trials demonstrating safety in humans, with a third clinical trial underway.

#### WHAT MAKES IT FIERCE:

"We're doing something no one else even thought to do that is true, fundamental disruption that affects the entire biotech industry," Imran said. "The RaniPill will advance the delivery of oral biologics and increase patient adherence."

#### WHAT TO LOOK FOR:

Imran said to expect a flurry of partnership activity in the next 12 to 18 months that would likely include additional funding. He said the RaniPill will likely get in front of the FDA for approval sometime in 2027.



# theranica

#### MEDICAL DEVICE INNOVATION

CEO: ALON IRONI BASED: TEL AVIV, BRIDGEWATER, NEW JERSEY FOUNDED: 2016 NERIVIO MIGRAINE NEUROBAND



#### WHAT'S THE SCOOP:

Theranica's Nerivio, a prescription wearable device used to mitigate migraines, went from being a reactive approach of treating symptoms to a proactive tool for helping prevent them. Earlier this year and just a few months after submitting a new 510(k) to expand indications for the technology, the FDA cleared the device for people who experience migraines with or without aura and who are at least 12 years old. "Our mission is to provide these patients with a platform that's not only a device but a tool to manage the disease and elevate their quality of life," Alon Ironi, Theranica's chief executive, said. "You use the device (therapy) in order to reduce the frequency of occurrence and in some cases to reduce the intensity." Patients wrap the Nerivio armband around their upper arm and use a connected smartphone app to start and stop the treatment and control its intensity. Electrodes embedded in the armband emit electrical pulses to nearby peripheral nerves that trigger internal pain management mechanisms, with the resulting pain relief spreading throughout the nervous system to reach the brain. "Our overall vision was to develop a non-invasive, drug-free approach to address acute migraines," Ironi said.

#### WHAT MAKES IT FIERCE:

It's personal, Ironi said. For him it was his daughter who has migraines that motivated him to find a treatment. And it's personal for the Theranica team. "They really care about people with migraines and they take the extra mile or 10 miles to show they care," he said. "These are the qualities that make us Fierce—the difference here is the fire inside."

#### WHAT TO LOOK FOR:

Expect the company to grow in three dimensions, Ironi said. The first is commercial, specifically growing in the U.S. with more medical liaisons and extending its coverage with health insurers, with related announcement expected in the next few months. The second dimension is geographic. Theranica is eyeing expansion beyond the U.S. and has partnered with Dr. Reddy's in India and is working to Brin the device to China and Japan. The third dimension is products as Theranica is developing a new therapy to help treat an unnamed chronic disease.



### **TeleScan**<sup>®</sup>

#### **TECHNOLOGY INNOVATION**


CEO: BLANCA LESMES BASED: AUSTIN, TEXAS FOUNDED: 2005 TELESCAN®

#### Identifying Pregnancy Complications IMPROVE MATERNAL CARE WITH TELESONOGRAPHY®



More than 5 million women in the US live in areas where there is limited or no access to skilled sonographers and maternal-fetal care.<sup>1</sup> This can lead to long-term health complications or even loss of life.

Bringing expert sonographers closer to patients can improve detection rates by up to 60%, leading to better outcomes.



#### WHAT'S THE SCOOP:

The mission of BB Imaging's TeleScan, a technology solution that links healthcare providers with remote sonographers to make ultrasound more accessible, is reducing maternal morbidity and mortality. About 36% of counties in the U.S. gualify as maternity care deserts. According to the Centers for Disease Control and Prevention, maternal causes of death in the U.S. grew from 20.1 deaths per 100,000 live births in 2019 to 32.9 in 2021. "There is a shortage of people in healthcare that do prenatal screening that has left many women—mom's and future mom's—out in the cold," Blanca Lesmes, chief executive of BB Imaging, said. "One of the key issues women are facing is a lack of focus on women's health. I got tired of the complacency and for the technology to catch up, so we decided software was the way to move forward." TeleScan works by having non-sonographer health-care workers upload short ultrasound videos (cine clips) to the platform, which are then reviewed by certified maternal-fetal medicine telesonographers. They produce a preliminary report for providers to review that can be accessed remotely, and patients can opt to have selected images sent to their phones. With TeleScan, ultrasounds can meet the needs of underserved areas and without requiring patients to travel long distances, endure long waits or go without care. "We feel like it's not okay for our sisters and friends not to have this prenatal service," Lesmes said.

#### WHAT MAKES IT FIERCE:

"We're scrappy, unafraid and able to act, that's what makes us Fierce," Lesmes said. "And the fact that we've been willing to tackle one of the key issues facing women today."

#### WHAT TO LOOK FOR:

Look for the company to start working with an AI model in order to extend its reach and make TeleScan more scalable on a global scale in the next two to three years. "We want women in all corners of the plant to have access," Lesmes said. BB Imaging also expects to be working with more partners and health systems to implement TeleScan. As an example, the company has been pitching to potential partners in Alaska "because there is no one in the state doing screening," she said.



**BIOTECH INNOVATION** MEDICAL DEVICE INNOVATION JURATA Watch. **ITERATIVE** •••• Rarebase Noah Medical SERVIER \* HEALTH™ IVWATCH PATIENT MONITOR NOAH MEDICAL'S SKOUT®: IMPROVING POLYP JURATA'S THIN FILM TECHNOLOGY RAREBASE TIBSOVO® (IVOSIDENIB TABLETS) DETECTION THROUGH GALAXY PLATFORM AND SMARTTOUCH SENSOR COMPUTER VISION DATA ANALYTICS/BUSINESS INTELLIGENCE **TECHNOLOGY INNOVATION BostonGene** S MEDIDATA saama **Ö** CELLARES ) IgniteData HumanFirst kinnos CELL SHUTTLE (PRODUCT) OR IGNITEDATA'S ARCHER HUMANFIRST'S ATLAS BOSTONGENE -INTEGRATED DEVELOPMENT AND - EHR-TO-EDC DATA MEDIDATA DETECT PATIENT HIGHLIGHT FOR WIPES PRECISION MEASURES KASSANDRA(TM) - CELL SMART DATA QUALITY (SDQ) TRANSFER TECHNOLOGY DATA SURVEILLANCE MANUFACTURING ORGANIZATION PLATFORM DECONVOLUTION TOOL FOR CLINICAL TRIALS (IDMO) SMART FACTORY FOR CELL THERAPIES (SERVICE) DRUG DELIVERY TECHNOLOGY **DIGITAL HEALTH SOLUTIONS firefly**health Freespira **Y**iz.ai MEIRAGT<sub>X</sub> RèCode UROTRONIC FIREFLY HEALTH APP FIREFLY HEALTH APP SELECTIVE ORGAN VIZ ANEURYSM OPTILUME RIBOSWITCH PLATFORM TARGETING (SORT)

> LIPID NANOPARTICLE (LNP) PLATFORM



# Let's Connect. This is only the beginning of how we can help you reach your marketing goals.

CONTACT US: LSsales@Questex.com

Join the Life Sciences Innovation Awards mailing list. Get key awards updates and more.

Subscribe Now